X

Drug Profile

Osteogenic growth peptide 10-14 L

Alternative Names: OGP 10-14 L

Latest Information Update: 18 Mar 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abiogen Pharma
Class Peptides
Mechanism of Action Stem cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myelofibrosis

Highest Development Phases

Discontinued Myelofibrosis; Stem cell mobilisation

Most Recent Events

11 May 2006 Phase-I/II clinical trials in Stem cell mobilisation in Italy (IV-injection)
11 May 2006 No development reported - Phase-I for Myelofibrosis in Italy (IV-injection)
06 Oct 2003 Osteogenic growth peptide 10-14 L has received Orphan Drug Status for Myelofibrosis in Italy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com